




Ulf Jungnelius, MD  
CEO  
Board Certified Oncologist



Investor call  
November 2, 2020

# An additional licensing agreement that validates arfolitixorins potential

---



*Endo and its operating company Paladin has a very successful track record of commercializing innovative pharmaceutical products in Canada and our partnership with them will be an invaluable component of our strategy to ensure global access to arfolitixorin*

# Endo – ideal partner with successful track record

---

- Endo is a specialty pharmaceutical company with decades of proven success within commercialization and market approval for new medicines
  - Paladin, an operating company of Endo, is focusing on acquiring or in-licensing pharmaceutical products for the Canadian market
  - Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies
- Endo is listed on NASDAQ-GS (ENDP). Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania and Paladin has its headquarter in Montreal, Canada.

# The partnership – A compelling strategic rationale

---



- 1 Strong validation from a specialty pharmaceutical company
- 2 Significant deal value in relation to market size
- 3 Up to USD 23 million as upfront and milestone payments
- 4 Tiered royalties on net sales in solid double-digit figures
- 5 In par with commercialization strategy to ensure global access of arfolitixorin

# The partnership in detail


---

- The license agreement is focused on the registration and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Canada
- Isofol will remain as global sponsor of the AGENT study
- Isofol will be responsible for supplying the drug to Paladin and will retain all international development rights
- Paladin will be responsible for registrational filing
- Paladin will be responsible for the commercialization of arfolitixorin in Canada





# ISO FOL



## Q&A

### **Isofol Medical AB (publ)**

Biotech Center  
Arvid Wallgrens Backe 20  
SE-413 46 Göteborg, Sweden

[info@isofolmedical.com](mailto:info@isofolmedical.com)  
[www.isofolmedical.com](http://www.isofolmedical.com)